Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)_Chinese Journal of Evidence-Based Medicine

Authors：

LI Liushui , CHEN Jing , LIU Yang ,  LIU Xianjun

Beijing Luhe Hospital, Capital Medical University, Beijing 101149, P. R. China;

Corresponding?author：

LIU Xianjun, Email: xjxianjun@163.com

Keywords：

Drug evaluation; Drug selection; Multi-dimensional quantitative evaluation; Rapid-acting insulin analogue; Insulin aspart; Insulin lispro; Insulin glulisine

DOI：

10.7507/1672-2531.202403100

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective This study aims to conduct a multi-dimensional quantitative evaluation of three rapid-acting insulin analogues, aspart (Novolog), lispro (Humalog), and glulisine (Apidra) to provide references for the selection of these drugs in medical institutions. Methods The recommended methods from the "Quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)" were employed to evaluate the pharmaceutical characteristics, effectiveness, safety, cost-effectiveness, and other attributes of the three rapid-acting insulin analogues. Results The total scores of insulins aspart (Novolog), lispro (Humalog), and glulisine (Apidra) were 73.5, 80.4, and 70.9, respectively. Insulin lispro (Humalog) had the highest score, demonstrating a prominent advantage in both effectiveness and cost-effectiveness dimensions. Conversely, insulin glulisine (Apidra) had the lowest score, with ratings in effectiveness and safety dimensions lower than those of the other two rapid-acting insulin analogs. Conclusion When selecting rapid-acting insulin analogs, healthcare institutions can choose one or more insulins, aspart (Novolog), lispro (Humalog), or glulisine (Apidra), all of which are strongly recommended, with priority given to insulin lispro (Humalog), which has the highest total score.

Citation： LI Liushui, CHEN Jing, LIU Yang, LIU Xianjun. Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition). Chinese Journal of Evidence-Based Medicine, 2024, 24(10): 1141-1148. doi: 10.7507/1672-2531.202403100 Copy

1.	趙志剛, 董占軍, 劉建平. 中國醫療機構藥品評價與遴選快速指南(第二版). 醫藥導報, 2023, 42(4): 447-456.
2.	美國衛生及公共服務部. 常見不良事件評價標準(CTCAE) 5.0版.
3.	國家醫保局, 人力資源社會保障部. 關于印發《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)》的通知.
4.	國家衛生健康委員會. 國家基本藥物目錄-2018年版.
5.	中國醫藥統計網. 2022年度中國醫藥工業百強企業榜單.
6.	中華醫學會糖尿病學分會. 中國2型糖尿病防治指南(2020年版). 中華糖尿病雜志, 2021, 13(4): 315-409.
7.	國家老年醫學中心, 中華醫學會老年醫學分會, 中國老年保健協會糖尿病專業委員會. 中國老年糖尿病診療指南(2024版). 中華糖尿病雜志, 2024, 16(2): 147-189.
8.	中華醫學會糖尿病學分會, 國家基層糖尿病防治管理辦公室. 國家基層糖尿病防治管理指南(2022). 中華內科雜志, 2022, 61(3): 249-262.
9.	中華醫學會內分泌學分會, 中華醫學會糖尿病學分會, 中國醫師協會內分泌代謝科醫師分會. 中國胰島素泵治療指南(2021年版). 中華內分泌代謝雜志, 2021, 37(8): 679-701.
10.	中華醫學會糖尿病學分會, 中國醫師協會內分泌代謝科醫師分會, 中華醫學會內分泌學分會, 等. 中國1型糖尿病診治指南(2021版). 中華糖尿病雜志, 2022, 14(11): 1143-1250.
11.	中華醫學會, 中華醫學會臨床藥學分會, 中華醫學會雜志社, 等. 2型糖尿病基層合理用藥指南. 中華全科醫師雜志, 2021, 20(6): 615-630.
12.	中華醫學會, 《中華全科醫師雜志》編輯委員會, 《基層2型糖尿病胰島素應用專家共識》編寫專家組. 基層2型糖尿病胰島素應用專家共識. 中華全科醫師雜志, 2021, 20(7): 726-736.
13.	American Diabetes Association Professional Practice Committee. Erratum. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 2024, 47(Suppl.1): S158-S178.
14.	Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract, 2022, 28(10): 923-1049.
15.	Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021, 27(6): 505-537.
16.	賈偉平, 包玉倩, 繆珩, 等. 兩種門冬胰島素治療糖尿病的有效性及安全性比較: 多中心、隨機、開放、對照試驗. 中華內科雜志, 2021, 60(12): 1148-1156.
17.	金仙, 張金蘋, 邊芳, 等. 重組賴脯胰島素治療糖尿病的療效及安全性: 多中心、隨機、陽性藥物平行對照臨床試驗. 中華糖尿病雜志, 2020, 12(12): 974-980.
18.	Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract, 2007, 76(2): 304-312.

1. 趙志剛, 董占軍, 劉建平. 中國醫療機構藥品評價與遴選快速指南(第二版). 醫藥導報, 2023, 42(4): 447-456.
2. 美國衛生及公共服務部. 常見不良事件評價標準(CTCAE) 5.0版.
3. 國家醫保局, 人力資源社會保障部. 關于印發《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)》的通知.
4. 國家衛生健康委員會. 國家基本藥物目錄-2018年版.
5. 中國醫藥統計網. 2022年度中國醫藥工業百強企業榜單.
6. 中華醫學會糖尿病學分會. 中國2型糖尿病防治指南(2020年版). 中華糖尿病雜志, 2021, 13(4): 315-409.
7. 國家老年醫學中心, 中華醫學會老年醫學分會, 中國老年保健協會糖尿病專業委員會. 中國老年糖尿病診療指南(2024版). 中華糖尿病雜志, 2024, 16(2): 147-189.
8. 中華醫學會糖尿病學分會, 國家基層糖尿病防治管理辦公室. 國家基層糖尿病防治管理指南(2022). 中華內科雜志, 2022, 61(3): 249-262.
9. 中華醫學會內分泌學分會, 中華醫學會糖尿病學分會, 中國醫師協會內分泌代謝科醫師分會. 中國胰島素泵治療指南(2021年版). 中華內分泌代謝雜志, 2021, 37(8): 679-701.
10. 中華醫學會糖尿病學分會, 中國醫師協會內分泌代謝科醫師分會, 中華醫學會內分泌學分會, 等. 中國1型糖尿病診治指南(2021版). 中華糖尿病雜志, 2022, 14(11): 1143-1250.
11. 中華醫學會, 中華醫學會臨床藥學分會, 中華醫學會雜志社, 等. 2型糖尿病基層合理用藥指南. 中華全科醫師雜志, 2021, 20(6): 615-630.
12. 中華醫學會, 《中華全科醫師雜志》編輯委員會, 《基層2型糖尿病胰島素應用專家共識》編寫專家組. 基層2型糖尿病胰島素應用專家共識. 中華全科醫師雜志, 2021, 20(7): 726-736.
13. American Diabetes Association Professional Practice Committee. Erratum. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 2024, 47(Suppl.1): S158-S178.
14. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract, 2022, 28(10): 923-1049.
15. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021, 27(6): 505-537.
16. 賈偉平, 包玉倩, 繆珩, 等. 兩種門冬胰島素治療糖尿病的有效性及安全性比較: 多中心、隨機、開放、對照試驗. 中華內科雜志, 2021, 60(12): 1148-1156.
17. 金仙, 張金蘋, 邊芳, 等. 重組賴脯胰島素治療糖尿病的療效及安全性: 多中心、隨機、陽性藥物平行對照臨床試驗. 中華糖尿病雜志, 2020, 12(12): 974-980.
18. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract, 2007, 76(2): 304-312.

Chinese Journal of Evidence-Based Medicine

Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content